PSMA-1007 is a prostate-specific membrane antigen (PSMA)-targeted radioligand primarily used as a diagnostic agent in positron emission tomography (PET) imaging for the detection and staging of prostate… Read more
PSMA-1007 is a prostate-specific membrane antigen (PSMA)-targeted radioligand primarily used as a diagnostic agent in positron emission tomography (PET) imaging for the detection and staging of prostate cancer. By binding specifically to PSMA receptors overexpressed on the surface of prostate cancer cells, this molecule enables precise visualization of primary and metastatic lesions. This category offers essential related compounds, including impurities and specialized reference standards, required to support the development and manufacture of this radiopharmaceutical. Laboratories utilize these high-quality materials for critical analytical tasks, such as impurity profiling, the validation of analytical methods, and rigorous quality control protocols. The availability of these characterized standards ensures that researchers can accurately evaluate the chemical integrity and performance of the radiotracer throughout its clinical lifecycle, supporting both development and regulatory compliance in nuclear medicine research.